Archive for Stock Market News

S&P500 Mini Speculators decreased their bearish bets for 2nd week

March 23rd – By CountingPips.comReceive our weekly COT Reports by Email

S&P500 Mini Non-Commercial Speculator Positions:

Large stock market speculators continued to trim their bearish net positions in the S&P500 Mini futures markets this week, according to the latest Commitment of Traders (COT) data released by the Commodity Futures Trading Commission (CFTC) on Friday.

The non-commercial futures contracts of S&P500 Mini futures, traded by large speculators and hedge funds, totaled a net position of -48,034 contracts in the data reported through Tuesday March 19th. This was a weekly increase of 18,864 net contracts from the previous week which had a total of -66,898 net contracts.

The week’s net position was the result of the gross bullish position (longs) tumbling by -9,991 contracts to a weekly total of 329,711 contracts but being more than offset by the gross bearish position (shorts) which saw a decline by -28,855 contracts for the week to a total of 377,745 contracts.

The net speculator position has been shedding their bearish bets for two straight weeks and for three out of the past four weeks. Speculators turned negative on this market late in January well after the sharp market drops in December and have overall been caught on the wrong side of the market during the run-up in January, February and March.

S&P500 Mini Commercial Positions:

The commercial traders position, hedgers or traders engaged in buying and selling for business purposes, totaled a net position of 45,543 contracts on the week. This was a weekly decline of -18,526 contracts from the total net of 64,069 contracts reported the previous week.

S&P500 Mini Futures:

Over the same weekly reporting time-frame, from Tuesday to Tuesday, the S&P500 Mini Futures (Front Month) closed at approximately $2836.50 which was an uptick of $39.25 from the previous close of $2797.25, according to unofficial market data.

*COT Report: The COT data, released weekly to the public each Friday, is updated through the most recent Tuesday (data is 3 days old) and shows a quick view of how large speculators or non-commercials (for-profit traders) as well as the commercial traders (hedgers & traders for business purposes) were positioned in the futures markets.

The CFTC categorizes trader positions according to commercial hedgers (traders who use futures contracts for hedging as part of the business), non-commercials (large traders who speculate to realize trading profits) and nonreportable traders (usually small traders/speculators).

Find CFTC criteria here: (http://www.cftc.gov/MarketReports/CommitmentsofTraders/ExplanatoryNotes/index.htm).

Article By CountingPips.comReceive our weekly COT Reports by Email

Weatherford International & 21st Century Fox lead Weekly top Gainers/Losers

By IFCMarkets

Top Gainers – The World Market

1. Weatherford International Ltd. – quotations of the American oil and gas service company.

2. China Evergrande Group – quotations of the Hong Kong real estate company and real estate operator.

market sentiment ratio long short positions

 Top Losers – The World Market

1. 21st Century Fox Inc. – quotations of the American media company and film-maker.

2. Deutsche Lufthansa AG – quotations of the German airline.

market sentiment ratio long short positions

 Top Gainers – Foreign Exchange Market (Forex)

1. GBPAUD, GBPCAD – the growth of this chart means the strengthening of the British pound against the Australian and Canadian dollars.

2. EURUSD, EURHKD – the growth of this chart means the strengthening of the euro against the US and Hong Kong dollars.

market sentiment ratio long short positions

 Top Losers – Foreign Exchange Market (Forex)

1. USDMXN, USDRUB – the decrease in this chart indicates the strengthening of the Mexican peso and the Russian ruble against the US dollar.

2. USDSEK, GBPSEK – the decrease in this chart indicates the strengthening of the Swedish krona against the British pound and the US dollar.

market sentiment ratio long short positions

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Russell 2000 Leads The Way For Technical Analysts

By TheTechnicalTraders.com

The Russell 2000 ETF continues to deliver critical technical and longer-term price patterns for skilled technicians.  Combining the IWM chart with the Transportation Index, Oil, Gold, and others provide a very clear picture of what to expect in the immediate future.

Recently, we posted a research article about the Head-n-Shoulders pattern setting up in the $INDU.  Again, the IWM chart is also showing a very clear Head-n-Shoulders pattern with critical resistance near $159.50 and support near $144.25.  Our researchers, at Technical Traders Ltd., believe this right Shoulder will prompt a downside market move towards support near $144.25 before a downward sloping wedge pattern sets up.  This first downward price leg will setup and congesting wedge formation that will, eventually, break to the upside and drive market prices higher.

We authored a research article about this pattern setup on February 17, 2019.  You can read it here.

Skilled traders watch all the charts to assist them in identifying characteristics that can assist them in understanding price moves, key support/resistance levels, and price patterns.  This IWM chart should be on everyone’s radar at the moment.  Where the IWM finds support, so will the other US stock market indexes.

WEEKLY IWM RUSSELL 2000 INDEX PATTERN

 

The IWM setup indicates we may only see a 5~7% downside price swing before support is found.  We’ll have to watch how this plays out over the next few weeks/months to determine if the $144.25 level is true support or if the lower $137.00 level will become support.  Either way, the downside price swing appears poised to unfold over the next few days/weeks – so be prepared.

Please take a minute to visit TheTechnicalTraders.com to learn how we can help you find and execute better trades in 2019.  We have already positioned our clients for this move and we believe we can help you stay ahead of these markets.  Visit www.TheTechnicalTraders.com/FreeResearch/ to read all of our most recent research.

Chris Vermeulen

 

Antibody Therapeutics Developer to Present at March Alzheimer’s/Parkinson’s Conference

By The Life Science Report

Source: Streetwise Reports   03/19/2019

The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it will present data in support of its new antibody candidates for Parkinson’s disease, at the 2019 Alzheimer’s & Parkinson’s Diseases Congress later this month.

Specifically at the conference, Dr. Neil Cashman, ProMIS’ chief scientific officer, will deliver the podium presentation, “Targeting of Pathogenic Aggregated Alpha-Synuclein: Refining Antibody Epitopes by Design,” on March 31. In it he will use ProMIS’ preclinical data to explain how the company developed antibodies that selectively bind to toxic forms of alpha-synuclein while sparing the healthy forms of it the body needs. The antibodies also block both, in vitro, the neurotoxicity and spread of the toxic forms of alpha-synuclein, which are considered a root cause of Parkinson’s.

On the prior day, March 30, Cashman will co-moderate the panel discussion, “Disease Mechanisms in Alzheimer’s and Parkinson’s Diseases.”

The AD/PD conference will take place March 26 to 31, 2019 in Lisbon, Portugal.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.

( Companies Mentioned: PMN:TSX; ARFXF:OTCQB,
)

Technology rally leads US stocks higher

By IFCMarkets

Dollar strengthens as Philadelphia Fed index recovers

US stock market rebounded on Thursday led by technology. The S&P 500 rose 1.1% to 2854.88 led by 3.7% Apple surge on analysts’ upgrade. The Dow Jones industrial average advanced 0.8% to 25709.94. Nasdaq composite index rallied 1.4% to 7630.91. The dollar weakening stalled as the Philadelphia Fed’s business activity index rebounded in March indicating improving conditions. The live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, rose 0.4% to 96.31 but is lower currently. Futures on US stock indexes point to mixed openings today.

FTSE 100 rise as EU agrees to Brexit delay

European stocks ended marginally lower on Thursday. EUR/USD joined GBP/USD’s slide as the Bank of England held interest rates steady, as widely expected. Both pairs are higher currently. The Stoxx Europe 600 index slipped 0.04%. Germany’s DAX 30 lost 0.5% to 11549.96. France’s CAC 40 slid 0.1% while UK’s FTSE 100 advanced 0.9% to 7185.43 as European Union agreed to postpone Britain’s March 29 departure to May 22 if the UK parliament approves Prime Minister Theresa May’s amended deal with the EU next week. In case of another rejection Britain will have until April 12 to “indicate a way forward.”

GB100 climbing above resistance line    03/22/2019 Market Overview IFC Markets chart

Asian indices inch higher

Asian stock indices are mostly higher today. Nikkei ended 0.1% higher at 21627.34 with yen little changed against the dollar. China’s stocks rose as Beijing confirmed Thursday that US Trade Representative Lighthizer and Treasury Secretary Mnuchin will visit China on March 28-29, while Chinese Vice Premier Liu He will travel to Washington early next month to continue the negotiations. The Shanghai Composite Index rose 0.1% and Hong Kong’s Hang Seng Index is 0.1% higher. Australia’s All Ordinaries Index extended gains 0.5% with Australian dollar flat against the greenback.

Brent retraces up

Brent futures prices are gaining today. Prices declined yesterday: Brent for May settlement closed 0.9% lower at $67.86 a barrel on Thursday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Biopharma Expected to Bring ‘Two First-in-Class Antibiotics to Market in 2019’

By The Life Science Report

Source: Streetwise Reports   03/19/2019

The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report.

In a March 13 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Nabriva Therapeutics Plc (NBRV:NASDAQ) has two antibiotics up for approval this year, which H.C. Wainwright & Co. believes the FDA will grant. The medications are CONTEPO and lefamulin, whose Prescription Drug User Fee Act (PDUFA) dates are April 30 and August 19, respectively.

CONTEPO (intravenous fosfomycin) is a broad-spectrum antibiotic for complicated urinary tract infections. “Importantly, CONTEPO has activity against key multidrug-resistant organisms,” Arce pointed out. CONTEPO has fast track and priority review statuses.

When its PDUFA date arrives in six weeks, CONTEPO is “very likely to be approved by the FDA,” an event that “could represent a meaningful stock catalyst, especially as investors position themselves ahead of the PDUFA of lefamulin,” Arce commented.

In support of such an outcome is the fact that IV fosfomycin is a generic in Europe where, in the 45 years of its use, it has proven to be both safe and efficacious. Also, in the ZEUS clinical trial, CONTEPO was shown to be noninferior to Zosyn (piperacillin-tazobactam).

Should the FDA approve CONTEPO in April, Nabriva is expected to launch it in mid-2019, noted Arce. The company intends to target facilities where antibiotic resistance rates are at a level that warrants use of a new antibiotic. Arce indicated such a “highly targeted approach” is appropriate and would likely result in “early-adopter sales and uptake,” particularly in light of the drug’s long-term history of use outside of the U.S.

However, significant demand-driven growth in sales of CONTEPO realistically will not likely occur until mid-2020, wrote Arce.

As for lefamulin, a larger opportunity with priority review status, according to Arce, it is expected to be approved and then launched in the fall. Nabriva anticipates it and CONTEPO, which are complementary in the hospital setting, will “share call points and utilize the same focused commercial, medical affairs and supply chain infrastructure.”

In other lefamulin news, last month a licensee of the antibiotic, Sinovant Sciences Ltd., submitted a clinical trial application to Chinese regulators seeking approval to evaluate it for community-acquired bacterial pneumonia. That milestone spurred the first payment to Nabriva, which was $1.5 million. Nabriva plans to license lefamulin in additional regions outside of the U.S., such as the European Union and Japan, to generate additional nondilutive capital.

Finally, Arce relayed that in Q4/18, Nabriva reported a net loss of $30.8 million, or $0.46 per basic and diluted share. For 2018, the firm’s net loss was $114.8 million, or $2.26 per basic and diluted share. At year-end 2018, the biopharma had $102.2 million of cash, sufficient to fund operations into Q2/20 according to management.

H.C. Wainwright & Co. has a Buy rating and a price target of $9 per share on Nabriva, which represents a triple, as the stock is currently trading at around $2.98 per share.

Editor’s note: a earlier version of this article incorrectly referred to CONTEPO and lefamulin as vaccines. They are antibiotics. We apologize for this error.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

( Companies Mentioned: NBRV:NASDAQ,
)

Cannabis Firm Announces Brand for Recreational Aficionados

By The Life Science Report

Source: Streetwise Reports   03/19/2019

This Canadian company intends to next launch a marketing campaign for the new product suite.

Sproutly Canada Inc. (SPR:CSE; SRUTF:OTCQB) announced in a news release it has a new cannabis brand for the recreational market called CALIBER, “designed for the cannabis connoisseur and delivered via the company’s craft cannabis flower production.”

“It is our belief that there is an opportunity within the consumer space for a premium brand backed by consistent and superior product quality,” Vice President of Marketing and Sales Melise Panetta said in the release.

Under the CALIBER brand, Sproutly will market small-batch flower and smokable products produced at its Toronto Herbal Remedies facility.

Once the company receives a sales license from Health Canada, it intends to launch a campaign for CALIBER that would feature production information and education and provide the vision behind and the highlights of the brand.

“CALIBER is targeted to adults who are looking for a brand distinguished by its consistently premium quality flower and smokable products. As consumers begin to navigate the newly legalized recreational cannabis market, it is our belief that there is an opportunity within the consumer space for a premium brand backed by consistent and superior product quality,” Melise Panetta, vice president of marketing and sales, stated.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Sproutly Canada. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Sproutly Canada. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sproutly Canada, a company mentioned in this article.

( Companies Mentioned: SPR:CSE; SRUTF:OTCQB,
)

Tech Firm to Offer Solution to Inefficient, Expensive Health Clinic Business Model

By The Life Science Report

Source: Streetwise Reports   03/20/2019

The company will roll out virtual, remote medical services to change how primary care practices are run.

Premier Health Group Inc. (PHGI:CSE; PHGRF:OTCQB; 6PH:FSE) plans to offer the medical services of nurses, medical office assistants and office managers virtually and remotely to primary care clinics, first to those in British Columbia that use the Juno EMR system followed by expansion into other provinces. This new offering is made possible by Premier Health’s recent acquisition of Cloud Practice.

Premier Health plans to introduce to Juno EMR users a virtual artificial intelligence (AI)-powered phone assistant along with a shared medical office assistant and office manager system. The former will prioritize and manage many of the repetitive tasks involved in patient care, and the latter will handle the back-end administrative tasks of running the clinic. As an added service, Premier Health will provide its templates for the various manuals required in clinics, such as those for privacy and training.

The news release cites the benefits of using such a suite of virtual services. It should help improve workflow and boost clinic efficiency by managing the electronic medical record documentation, the day-to-day operations and other administrative tasks. It should help reduce the patient backlog and patients’ long wait times. It could improve the quality of care provided and patient outcomes. It should increase revenue by allowing physicians to concentrate on seeing patients, determining diagnoses and devising treatment plans and leaving the other work to nurses, medical assistants and office managers, and not have to pay for dedicated staff to fill those roles.

By Q3/19, Premier Health intends to add remote shared billing services, including detection of missed charges, mistakes and the like.

“These offerings will transform the primary care landscape from a fixed labor cost to a variable cost model that is customized for the individual needs of clinics,” according to the release. “This increased efficiency and lower operating cost will increase the overall profitability of primary care clinics.”

“From my own clinical experience, I see the benefit of offering these services to other privately owned clinics,” said Dr. Essam Hamza, CEO of Premier Health. “We have successfully integrated shared resources across our four HealthVue Medical clinics. With rising labor costs, many clinics simply cannot afford dedicated staffing. With our recent acquisition of Cloud Practice, we have the opportunity to provide virtual and remote services to the 287 clinics currently using Juno EMR.”

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Premier Health Group Inc. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Premier Health Group Inc., a company mentioned in this article.

( Companies Mentioned: PHGI:CSE; PHGRF:OTCQB; 6PH:FSE,
)

5 Small-Caps on Fund Manager Steve Palmer’s Radar Screen

By The Life Science Report

Source: Streetwise Reports   03/19/2019

Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention.

Streetwise Reports: Steve, would you give us an overview of the AlphaNorth Capital Conference?

Steve Palmer: We held our 6th conference in Nassau, Bahamas, in January; it’s focused on small-cap non-resource companies. This past year we had a lot of technology and cannabis companies. There were also healthcare and consumer products companies.

SWR: How many companies attend the conference?

SP: It’s grown every year since we started it. This year we had three tracks with 18 companies in each track.

SWR: Would you tell us about a couple of the companies that you’re excited about?

SP: One that I’m particularly excited about is Vancouver-based Jackpot Digital Inc. (JP:TSX.V; JPOTF:OTCQB; LVH1:FSE). It has developed an electronic poker table that is like a giant touchscreen. It eliminates the requirement for a dealer, so casino operators are very keen to have this because it lowers their costs. Also, with poker there’s some idle time with the players. If you fold early on in the hand, let’s say, you’re just sitting there waiting for everybody else to finish. But at your station, you can switch, and you can play electronic blackjack on the table, for example. So it keeps the players engaged, and it generates more revenue than a typical table would.

SWR: At what stage is the company now? Is its product in use or is it still in the prototype phase?

SP: It has tables in use. It has a new generation table that it’s getting orders for now. It has a bunch of its older generation tables currently in use, mostly on Carnival ships. It has current orders for 30 new generation tables to ship in the next few months. It just did a small private placement to fund the building of those tables.

What’s exciting about Jackpot Digital is the product, and it’s getting lots of new orders now. It’s at an inflection point, in my view, of turning cash flow positive. When these tables go out, they are expected to generate about $5,000 per month each to the company.

SWR: The company receives a share of the earnings of the table?

SP: Yes, that’s how it works in most places. Jackpot Digital has recently won some orders in France, where the rules are different. The casino industry is very regulated, and in France you’re not allowed to take a share of the winnings. So Jackpot sells the tables outright, and it’s building a couple for there right now.

We’re pretty excited about the company; it’s just getting to the critical mass now where it’s going to be cash flow positive and the momentum on the table orders is ramping up. The biggest hurdle the company faces is having enough working capital to facilitate orders, which is a good problem to have.

SWR: What is the next company you’d like to talk about?

SP: Another company at the conference I like is in the cannabis sector. I don’t normally talk about cannabis companies because I’m not a huge fan of the sector in general. It’s LiveWell Canada Inc. (LVWL:CSE; LXLLF:OTCMKTS). Its shares are currently halted. It’s going to be a CBD extraction company, and it’s going to be one of the largest producers of cannabidiol (CBD) oil using hemp. The change with the Farm Bill in the U.S. has really ignited this industry, and there’s a huge demand. LiveWell is getting very good margins, and it’s just ramping up a big facility in Montana to produce CBD oil.

The numbers are actually quite silly, if you believe them, in terms of what the going rate is for CBD oil and the volumes that these guys are going to be able to produce.

SWR: Do you expect, as more CBD oil comes out onto the market, that prices might go to a more reasonable level? Are states regulating prices?

SP: The states are not meddling in the pricing. It’s the supply and demand that’s created a very strong pricing environment. I’ve asked many of the operators in the space about it because obviously these prices can’t stay where they are indefinitely. People involved in the space believe that there’s going to be maybe a two- to three-year window where prices will stay where they’re at until the supply catches up to the demand. But you’re right, over the longer term, these kind of prices won’t last. For example, CBD oil sells for $6,500–10,000 per kilogram; that’s the going rate right now. And it’s been at that level for many months. And LiveWell is producing at less than $500/kg, so it has very strong margins.

LiveWell is currently merging with a company called Vitality CBD Natural Health Products Inc., and that’s expected to close in the next few weeks. It is guiding to having the stock back trading in March. So I’m excited to see, when it starts trading, how investors react to that.

SWR: Is this a merger of equals or is LiveWell acquiring Vitality?

SP: It’s a reverse takeover situation, and Vitality’s the bigger entity. It is acquiring LiveWell.

SWR: You mentioned LiveWell is building a large facility in Montana. Does it have other facilities also at this point?

SP: LiveWell is producing currently out of another, much smaller facility. The Montana facility is going to have a huge capacity. LiveWell announced recently that it produced 200 kg of CBD equivalent in the first week of February. It expects to ramp that up to 200 kg per day by the second half of 2019. So if you do the math on that, at US$6,500 per kg, that’s US$1.3 million a day in product. So you can get to some pretty big numbers.

SWR: Is there anything else you want us to know about this company?

SP: Just that its numbers look very attractive to me based on the current pricing environment and it should be trading sometime this month. It has plans for a U.S. listing shortly thereafter. So it could be quite an exciting one to watch.

SWR: What is the next company?

SP: Another one I like that was at the conference is Assure Holdings Corp. (IOM:TSX.V; ARHH:OTCQB). This is an interesting one because it has some decent revenue already. It has equipment for neuromonitoring certain surgical procedures, and it’s only in one or two states at the moment. But it has expansion plans to move into other states in the United States. Revenue in 2018 was about $25 million with roughly $15 million in earnings. The revenue growth profile, once it starts adding these other states, is quite significant.The company is forecasting a 70% increase in revenue growth for 2019.

SWR: Any other companies you would like to mention?

SP: Avivagen Inc. (VIV:TSX.V) is worth talking about; it’s fairly timely. The company recently received a very significant order in the U.S. for its product, OxC-beta. It’s a proprietary supplement that it has developed that it can put into animal feed, and the trials have shown that the animals, compared to the control group, are healthier and they grow more quickly. It eliminates the need, in many cases, for adding antibiotics to the animal feed.

My understanding is the initial volumes for the U.S. are fairly significant. It has been selling into East Asia, the Philippines mainly, for the last several quarters, and that’s been ramping nicely. But the U.S. market is much larger, the second largest market in the world, I believe, for animal feed. So we think this is going to be a huge catalyst for the company. The third largest market in the world is Brazil, and we think that it will probably follow suit in ordering product now that the U.S. seems to be on board. There have been many trials that show that the product works. There’s a big initiative to cut back on the use of antibiotics in animals, and this is a theme that we like.

SWR: Do you have a final company for us?

SP: Yes, I could mention one more. It’s a Vancouver-based electric bus manufacturer, GreenPower Motor Company Inc. (GPV:TSX.V; GPVRF:OTCQX). It’s making great gains. It’s one of the few companies that I’ve come across in the last year that has actually exceeded its expectations in guidance. It is selling buses mainly into the California market, where there are huge incentives for school districts and other transportation municipalities to switch to electric buses. It is ramping up production this year. It should more than triple revenue in 2019 versus 2018.

SWR: Thanks for your insights, Steve.

Steve Palmer is a Founding Partner, President and Chief Investment Officer of AlphaNorth Asset Management and currently manages the award-winning AlphaNorth Partners Fund, AlphaNorth Growth Fund and AlphaNorth Resource Fund. Prior to founding AlphaNorth in 2007, Palmer was employed as Vice President at one of the world’s largest financial institutions, where he managed equity assets of approximately CA$350M. Palmer managed a pooled fund, which focused on Canadian small-capitalization companies, from its inception to August 2007, achieving returns of 35.8% annualized over a nine-year period, which ranked it No. 1 in performance by a major fund ranking service in its small-cap, pooled-fund category. Palmer earned a bachelor’s degree in economics from the University of Western Ontario and is a Chartered Financial Analyst.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Patrice Fusillo conducted this interview for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. She owns, or members of her immediate household or family own, shares of the following companies mentioned in this article: None. She is, or members of her immediate household or family are, paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this interview are billboard sponsors of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Steve Palmer: I, or members of my immediate household or family, and/or AlphaNorth funds, own shares of the following companies mentioned in this article: All of the companies mentioned. I, or members of my immediate household or family, are paid by the following companies mentioned in this article: None. My company has a financial relationship with the following companies mentioned in this interview: None. I determined which companies would be included in this article based on my research and understanding of the sector. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview.
4) The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, Jackpot Digital and Assure Holdings, companies mentioned in this article.

( Companies Mentioned: IOM:TSX.V; ARHH:OTCQB,
VIV:TSX.V,
GPV:TSX.V; GPVRF:OTCQX,
JP:TSX.V; JPOTF:OTCQB; LVH1:FSE,
LVWL:CSE; LXLLF:OTCMKTS,
)

Fed cuts rate hikes projections to zero

By IFCMarkets

Stocks fall and dollar weakens after dovish Fed

US stock market continued retreating on Wednesday led by bank shares after dovish Fed decision. The S&P 500 slid 0.3% to 2824.23. The Dow Jones industrial average fell 0.6% to 25745.67. Nasdaq composite index however added 0.1% to 7728.97. The dollar weakening accelerated as Federal Reserve cut the projection of the number of interest rate hikes expected this year to zero from the two forecast in December. The live dollar index data show the ICE US Dollar index, a measure of the dollar’s strength against a basket of six rival currencies, fell 0.6% to 95.94 and is lower currently. Futures on US stock indexes point to lower openings today.

DAX 30 leads European indices losses

European stocks turned lower on Wednesday with all sectors down. The EUR/USD accelerated its climb while the GBP/USD turned lower as the UK officially requested a delay to its departure from the EU. Both pairs are currently higher. The Stoxx Europe 600 fell 0.9% led by auto makers shares. Germany’s DAX 30 dropped 1.6% to 11603.89, France’s CAC 40 lost 0.8% and UK’s FTSE 100 slid 0.5% to 7291.01.

DE30 reflecting off MA(200) 03/21/2019 Market Overview IFC Markets chart

Shanghai Composite leads Asian indices higher

Asian stock indices are mostly higher today after dovish Fed decision. Nikkei added 0.2% to 21608.92 despite yen’s continued climb against the dollar. China’s stocks are mixed: the Shanghai Composite Index is up 0.4% while Hong Kong’s Hang Seng Index is 0.7% lower. Australia’s All Ordinaries Index inched up 0.03% despite the Australian dollar continued gain against the greenback.

Brent rises boosted by more US inventories drop

Brent futures prices are extending gains today. Prices rose yesterday after data showed US crude stockpiles fell by 9.6 million barrels last week with gasoline supplies dropping further. May Brent crude rose 1.3% to $68.50 a barrel on Wednesday.

Market Analysis provided by IFCMarkets

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.